NBIX
Neurocrine Biosciences Inc
143.20$
+1.8%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 253.5% | 305.4% | – | 1.0% | 0.7% | 0.8% | 1.3% | 0.9% | 1.0% | 1.2% | 0.8% | 0.9% | 1.0% | 1.0% | 0.9% | 0.8% | 1.0% | 1.2% | 1.2% | 1.1% | 1.4% | 1.3% | 1.5% | 1.3% | 1.6% | 1.9% | 2.0% | 2.5% | 2.2% | 1.6% | 1.5% | 1.6% | 1.3% | 1.5% | 1.6% | 1.6% | 1.8% | 2.2% | 1.7% | 2.4% | 2.0% | |
| 0.0% | -139.3% | – | 99.0% | 99.3% | 99.2% | 98.7% | 99.1% | 99.0% | 98.8% | 99.2% | 99.1% | 99.0% | 99.0% | 99.1% | 99.2% | 99.0% | 98.8% | 98.8% | 98.9% | 98.6% | 98.7% | 98.5% | 98.7% | 98.4% | 98.1% | 98.0% | 97.5% | 97.8% | 98.4% | 98.5% | 98.4% | 98.7% | 98.5% | 98.4% | 98.4% | 98.2% | 97.8% | 98.3% | 97.6% | 98.0% | |
| 139.6% | 150.6% | – | 345.2% | 37.0% | 27.1% | 68.9% | 38.2% | 23.4% | 29.7% | 27.2% | 33.6% | 20.4% | 22.7% | 24.6% | 26.8% | 26.7% | 26.9% | 30.9% | 25.9% | 31.3% | 28.0% | 32.9% | 35.9% | 27.8% | 28.6% | 33.2% | 32.2% | 28.5% | 26.7% | 30.9% | 32.4% | 31.3% | 29.6% | 46.0% | 35.5% | 31.5% | 32.1% | 36.4% | 34.1% | 33.5% | |
| 116.6% | 157.8% | – | 657.8% | 72.2% | 59.6% | 82.5% | 62.9% | 39.8% | 52.5% | 63.2% | 44.0% | 38.0% | 103.6% | 49.7% | 31.9% | 43.5% | 43.0% | 54.5% | 49.6% | 52.2% | 50.2% | 64.6% | 48.3% | 48.0% | 44.4% | 57.7% | 49.0% | 40.9% | 42.5% | 47.2% | 41.0% | 37.7% | 45.8% | 48.3% | 41.6% | 36.7% | 37.5% | 39.1% | 45.8% | 40.1% | |
| 256.2% | 308.3% | – | 1,003.0% | 109.2% | 86.7% | 151.3% | 101.0% | 63.2% | 82.2% | 172.2% | 80.4% | 58.4% | 79.0% | 74.3% | 73.9% | 116.1% | 69.9% | 85.5% | 77.2% | 83.5% | 78.2% | 97.5% | 84.3% | 75.8% | 73.0% | 125.1% | 81.2% | 69.4% | 69.2% | 79.3% | 73.8% | 69.2% | 75.9% | 94.3% | 77.2% | 68.2% | 71.6% | 75.5% | 81.6% | 74.6% | |
| -256.2% | -308.3% | – | -904.0% | -9.9% | 12.5% | -52.7% | -1.9% | 35.8% | 16.6% | -73.0% | 18.7% | 40.6% | 20.0% | 24.8% | 25.3% | -17.1% | 29.0% | 13.3% | 21.7% | 15.0% | 20.5% | 1.0% | 14.5% | 22.6% | 25.1% | -27.2% | 16.3% | 28.3% | 29.2% | 19.3% | 24.6% | 29.5% | 22.6% | 4.1% | 21.2% | 30.1% | 26.2% | 22.8% | 16.0% | 23.4% | |
| 0.0% | 130.2% | – | 75.2% | 12.1% | 7.8% | 10.6% | 7.8% | 5.1% | 5.9% | 5.7% | 4.3% | 3.6% | 3.3% | 3.5% | 2.7% | 3.3% | 3.1% | 2.7% | 2.1% | 2.2% | 2.1% | 0.8% | 0.6% | 0.3% | 0.3% | 0.3% | 0.3% | 0.2% | 0.2% | 0.2% | 8.4% | – | – | – | 0.0% | – | – | – | 0.3% | – | |
| -245.9% | -297.7% | – | -946.9% | -18.3% | 7.3% | -58.8% | -6.1% | 33.5% | 14.3% | -74.1% | 28.4% | 26.3% | 15.8% | 16.4% | 27.5% | -22.1% | 16.8% | 11.5% | 19.9% | 10.3% | -4.4% | 6.9% | -6.2% | 25.2% | 28.6% | -24.6% | 26.9% | 23.2% | 38.5% | 6.7% | 16.7% | 30.6% | 25.9% | 2.6% | 23.2% | 36.7% | 29.7% | 30.3% | 16.9% | 27.9% | |
| -10.3% | -13.5% | – | 75.2% | 12.1% | 7.1% | 10.6% | 7.8% | 5.1% | 0.6% | -0.3% | 0.4% | 2.1% | 1.9% | 0.6% | 1.2% | 0.2% | -123.5% | -2.1% | 5.3% | 2.7% | -2.1% | 2.4% | -1.7% | 7.6% | 7.0% | -6.4% | 5.8% | 6.5% | 9.8% | -1.7% | 5.7% | 9.7% | 9.5% | 1.2% | 7.6% | 10.4% | 10.6% | 6.0% | 1.9% | 7.0% | |
| -245.9% | -297.7% | – | -946.9% | -18.3% | 7.3% | -58.8% | -6.1% | 33.5% | 13.7% | -73.8% | 28.0% | 24.2% | 13.9% | 15.8% | 26.3% | -22.3% | 140.3% | 13.6% | 14.6% | 7.6% | -2.3% | 4.5% | -4.5% | 17.7% | 21.6% | -18.2% | 21.1% | 16.7% | 28.7% | 8.4% | 11.0% | 20.9% | 16.4% | 1.4% | 15.6% | 26.4% | 19.1% | 24.3% | 15.1% | 20.9% | |
| -243.2% | -305.4% | – | -862.3% | -5.2% | 15.9% | -47.2% | 2.6% | 39.2% | 21.2% | -67.3% | 33.7% | 30.8% | 20.0% | 20.8% | 31.0% | -17.9% | 20.9% | 15.3% | 22.9% | 13.5% | -1.3% | 8.8% | -4.5% | 26.6% | 30.0% | -23.1% | 28.0% | 24.5% | 39.8% | 21.6% | 26.3% | 30.8% | 28.9% | 5.5% | 24.3% | 37.7% | 29.2% | 23.7% | 19.8% | 27.2% |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.